NovaBay Pharmaceuticals, Inc.
NBY · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,041 | $857 | $2,048 | $14,595 |
| - Cash | $430 | $3,130 | $5,362 | $7,504 |
| + Debt | $1,672 | $2,740 | $2,041 | $551 |
| Enterprise Value | $3,283 | $467 | -$1,273 | $7,642 |
| Revenue | $9,781 | $10,455 | $14,404 | $10,204 |
| % Growth | -6.4% | -27.4% | 41.2% | – |
| Gross Profit | $6,481 | $6,084 | $7,781 | $6,515 |
| % Margin | 66.3% | 58.2% | 54% | 63.8% |
| EBITDA | -$5,925 | -$4,095 | -$7,197 | -$8,743 |
| % Margin | -60.6% | -39.2% | -50% | -85.7% |
| Net Income | -$7,223 | -$9,640 | -$10,608 | -$5,824 |
| % Margin | -73.8% | -92.2% | -73.6% | -57.1% |
| EPS Diluted | -2.53 | -138.65 | -353.59 | -184.09 |
| % Growth | 98.2% | 60.8% | -92.1% | – |
| Operating Cash Flow | -$5,183 | -$4,261 | -$6,654 | -$9,192 |
| Capital Expenditures | -$6 | -$19 | -$112 | -$52 |
| Free Cash Flow | -$5,189 | -$4,280 | -$6,766 | -$9,244 |